Study identification

EU PAS number

EUPAS4207

Study ID

44845

Official title and acronym

Outpatient care with long-acting bronchodilators: COPD Register in Germany (DACCORD)

DARWIN EU® study

No

Study countries

Germany

Study description

The DACCORD registry aims to close the apparent gap between populations in clinical trials and daily live by evaluating different treatment approaches in COPD with respect to their efficacy and tolerability and their impact on patient-related outcomes. DACCORD is a prospective observational German registry since November 2012, evaluating data of 16,000 COPD patients from approximately 700 sites distributed in three different cohorts. To guarantee the best selection under the conditions of a non-interventional study, patients have to fulfill the criteria for recruitment to the German COPD DMP (Disease Management Program), implemented by the statutory health insurances. The primary objective is to evaluate diagnosis and therapy of outpatient-treated COPD patients under special consideration of individual treatment success, determined by therapy adherence, symptoms and patient-reported outcomes. Among the secondary objectives are the characteristics of exacerbations and COPD progression, measured by lung function and CAT (COPD Assessment Test) questionnaire

Study status

Finalised
Research institutions and networks

Institutions

Multiple centres: 700 centres are involved in the study

Contact details

Novartis Clinical Disclosure Officer

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual:

Study start date

Actual:

Data analysis start date

Planned:
Actual:

Date of interim report, if expected

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Novartis Pharmaceuticals
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable